169 related articles for article (PubMed ID: 29592972)
1. Drug-induced movement disorder and confusion associated with duloxetine.
Siddiqui SH; Memon NA; Shanker R
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29592972
[TBL] [Abstract][Full Text] [Related]
2. A case of retrobulbar optic neuritis caused by duloxetine.
Bicer T; Kosker M; Celikay O; Gurdal C
Cutan Ocul Toxicol; 2016 Sep; 35(3):251-3. PubMed ID: 26362493
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine-related tardive dystonia and tardive dyskinesia: a case report.
Chen PY; Lin PY; Tien SC; Chang YY; Lee Y
Gen Hosp Psychiatry; 2010; 32(6):646.e9-646.e11. PubMed ID: 21112461
[TBL] [Abstract][Full Text] [Related]
4. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine in the long-term treatment of major depressive disorder.
Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
[TBL] [Abstract][Full Text] [Related]
6. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
[TBL] [Abstract][Full Text] [Related]
7. Restless legs syndrome associated with the combined use of duloxetine plus paroxetine.
Nikolaou KN; Michopoulos I; Douzenis A; Papazahos C; Papageorgiou C; Gournellis R
J Clin Psychopharmacol; 2015 Jun; 35(3):345-6. PubMed ID: 25815756
[No Abstract] [Full Text] [Related]
8. A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.
Lai CH; Hsu YY
Int J Neuropsychopharmacol; 2011 Mar; 14(2):225-35. PubMed ID: 20663271
[TBL] [Abstract][Full Text] [Related]
9. Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: A randomized, controlled trial.
Bansal R; Hellerstein DJ; Sawardekar S; O'Neill J; Peterson BS
PLoS One; 2019; 14(7):e0219679. PubMed ID: 31323045
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
12. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Emslie GJ; Wells TG; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2015 May; 25(4):293-305. PubMed ID: 25978741
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
14. Dysosmia and dysgeusia associated with duloxetine.
Yoshida K; Fukuchi T; Sugawara H
BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29170185
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics.
Perahia DG; Kajdasz DK; Royer MG; Walker DJ; Raskin J
Int Clin Psychopharmacol; 2006 Sep; 21(5):285-95. PubMed ID: 16877900
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine-related posterior reversible encephalopathy syndrome: A case report.
Zappella N; Perier F; Pico F; Palette C; Muret A; Merceron S; Girbovan A; Marquion F; Legriel S
Medicine (Baltimore); 2016 Aug; 95(33):e4556. PubMed ID: 27537580
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation.
Rovera C; Mauri MC; Bertin E; Di Pace C; Paletta S; Reggiori A; De Gaspari IF; Cattaneo D; Mari D; Altamura AC
Hum Psychopharmacol; 2016 Sep; 31(5):349-55. PubMed ID: 27400882
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine: a review of its use in the treatment of major depressive disorder.
Frampton JE; Plosker GL
CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine for the treatment of major depressive disorder.
Nemeroff CB; Schatzberg AF; Goldstein DJ; Detke MJ; Mallinckrodt C; Lu Y; Tran PV
Psychopharmacol Bull; 2002; 36(4):106-32. PubMed ID: 12858150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
